| DESCRIPTION | - A.M. JUBB et al., J. Pathol., (20010000), vol. 195, pages 111 - 134 | - |
| DESCRIPTION | - A.M. JUBB et al., J. Pathology, (20010000), vol. 195, pages 111 - 34 | - |
| DESCRIPTION | - ANSELL; S.M. et al., Mayo Clin. Proc., (20050000), vol. 80, no. 8, pages 1087 - 97 | - |
| DESCRIPTION | - APARICIO et al., Curr. Opin. Invest. Drugs, (20020000), vol. 3, no. 4, pages 627 - 33 | - |
| DESCRIPTION | - BELINSKY, S.A., Nature Rev. Cancer, (20040000), vol. 4, pages 1 - 11 | - |
| DESCRIPTION | - BENNETT J. M. et al., Ann. Intern. Med., (19850000), vol. 103, no. 4, pages 620 - 5 | - |
| DESCRIPTION | - BESA E. C., Med. Clin. North Am., (19920000), vol. 76, no. 3, pages 599 - 617 | - |
| DESCRIPTION | - BROWN et al., Biochemical Preparations, (19550000), vol. 4, pages 70 - 76 | - |
| DESCRIPTION | - B. S. SKIKNEM. R. WARDA. NASSERL. AUKERMANG. GARCIA-MANEROG. GARCIA-MANEROM. L. STOLTZM. R. WARDH. KANTARJIANS. SHARMA, Leukemia, (20080000), vol. 22, pages 1680 - 84 | - |
| DESCRIPTION | - CAS , no. 320-67-2 | - |
| DESCRIPTION | - EMENS, L.A. et al., Curr. Opinion Mol. Ther., (20010000), vol. 3, no. 1, pages 77 - 84 | - |
| DESCRIPTION | - FOSTER et al., Adv. Drug Res., (19850000), vol. 14, pages 1 - 36 | - |
| DESCRIPTION | - FROMMER, M. et al., Proc. Nat'l Acad. Sci. USA, (19920000), vol. 89, pages 1827 - 31 | - |
| DESCRIPTION | - GATELY, J. Nucl. Med., (19860000), vol. 27, page 388 | - |
| DESCRIPTION | - G. GIFFORD et al., Clin. Cancer Res., (20040000), vol. 10, pages 4420 - 26 | - |
| DESCRIPTION | - GORDON, Drug Metab. Dispos., (19870000), vol. 15, page 589 | - |
| DESCRIPTION | - GRUNDMANN et al., Chem. Ber., (19540000), vol. 87, pages 19 - 24 | - |
| DESCRIPTION | - JEMAL et al., CA Cancer J. Clin., (20050000), vol. 55, no. 1, pages 10 - 30 | - |
| DESCRIPTION | - J.G. HERMANS.B. BAYLIN, N. Engl. J. Med., (20030000), vol. 349, pages 2042 - 54 | - |
| DESCRIPTION | - K. APPLETON et al., J. Clin. Oncol., (20070000), vol. 25, no. 29, pages 4603 - 4609 | - |
| DESCRIPTION | - KUSHNER et al., Can. J. Physiol. Pharmacol., (19990000), vol. 77, pages 79 - 88 | - |
| DESCRIPTION | - LAIRD, P.W., Nature Rev. Cancer, (20030000), vol. 3, pages 253 - 66 | - |
| DESCRIPTION | - LI et al., Bioinformatics, (20020000), vol. 18, pages 1427 - 31 | - |
| DESCRIPTION | - LIJINSKY, Food Cosmet. Toxicol., (19820000), vol. 20, page 393 | - |
| DESCRIPTION | - LIJINSKY, J. Nat. Cancer Inst., (19820000), vol. 69, page 1127 | - |
| DESCRIPTION | - LIST et al., J. Clin. Oncol., (19900000), vol. 8, page 1424 | - |
| DESCRIPTION | - MANGOLD, Mutation Res, (19940000), vol. 308, page 33 | - |
| DESCRIPTION | - M.V. BROCK et al., N. Engl. J. Med., (20080000), vol. 358, no. 11, pages 1118 - 28 | - |
| DESCRIPTION | - P.A. JONESS.B. BAYLIN, Nature Rev. Gen., (20020000), vol. 3, pages 415 - 28 | - |
| DESCRIPTION | - PENICHET, M.L.MORRISON, S.L., J. Immunol. Methods, (20010000), vol. 248, pages 91 - 101 | - |
| DESCRIPTION | - P. FENAUX et al., Lancet Oncol., (20090000), vol. 10, no. 3, pages 223 - 32 | - |
| DESCRIPTION | - PISKALA, Collect. Czech. Chem. Comm., (19670000), vol. 32, pages 3966 - 3976 | - |
| DESCRIPTION | - PISKALA et al., Synthetic Procedures in Nucleic Acid Chemistry, Wiley Interscience, (19680000), vol. 1, pages 107 - 108 | - |
| DESCRIPTION | - P.M. DAS et al., Mol. Cancer, (20060000), vol. 5, no. 28 | - |
| DESCRIPTION | - RAO, K.V., American Journal of Health-System Pharmacy, (20070000), vol. 64, no. 17, pages 1799 - 1807 | - |
| DESCRIPTION | - SILVERMAN et al., Blood, (20050000), vol. 106, no. 11, page 2526 | - |
| DESCRIPTION | - SILVERMAN et al., J. Clin. Oncol., (20020000), vol. 20, no. 10, pages 2429 - 2440 | - |
| DESCRIPTION | - S. NAND et al., Leukemia and Lymphoma, (20080000), vol. 49, no. 11, pages 2141 - 47 | - |
| DESCRIPTION | - WADE, D., Chem. Biol. Interact., (19990000), vol. 117, page 191 | - |
| DESCRIPTION | - ZELLO, Metabolism, (19940000), vol. 43, page 487 | - |
| DESCRIPTION | - ZENT, C.S. et al., Current Oncology Reports, (20070000), vol. 9, pages 345 - 52 | - |
| DESCRIPTION | - ZIEMBA, A.J. et al., "Development of Oral Demethylating Agents for the Treatment of Myelodysplastic Syndrome", Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, (20090418), page 3369 | - |
| OPPOSITION | - Anonymous, "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, Onureg 200/300 mg film-coated tablets, SmPC for Onureg®", Celgene Distribution B.V., (20210101), pages 1 - 32, XP093253790 | - |
| OPPOSITION | - Anonymous, "Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001", Bristol Myers Squibb, (20191210), page 3pp, Bristol Myers Squibb, URL: https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Presents-Overall-Survival-and-Safety-Data-From-Pivotal-CC-486-Study-QUAZAR-AML-001/default.aspx, (20201001), XP055735907 | - |
| OPPOSITION | - Anonymous, "Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia", Press Releases, (20210618), pages 1 - 3, XP093253526 | - |
| OPPOSITION | - Anonymous, "European Medicines Agency ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE FOR GUIDANCE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES", (20060101), pages 1 - 32, URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002823.pdf, (20150904), XP055211303 | - |
| OPPOSITION | - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA", (20080801), page 1, XP055735918 | - |
| OPPOSITION | - Anonymous, "Onureg (azacitidine) EMA/243170 ", Overview of Onureg, European Medicines Agency, (20210601), pages 1 - 2, Overview of Onureg, URL: https://www.ema.europa.eu/en/documents/overview/onureg-epar-medicine-overview_en.pdf, XP093205527 | - |
| OPPOSITION | - Anonymous, "PRESS RELEASE: Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes", PRESS RELEASE, Fierce Biotech, (20070829), pages 1 - 5, PRESS RELEASE, URL: https://www.fiercebiotech.com/biotech/press-release-pharmion-s-oral-azacitidine-granted-fast-track-status-for-myelodysplastic, XP093205454 | - |
| OPPOSITION | - Anonymous, "SUMMARY OF PRODUCT CHARACTERISTICS: Vidaza", European public assessment report (EPAR) for Vidaza, European Medicines Agency, (20231207), pages 1 - 36, European public assessment report (EPAR) for Vidaza, URL: https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_en.pdf, XP093206670 | - |
| OPPOSITION | - Aparicio Ana; Weber Jeffrey S, "Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, US , (20020401), vol. 3, no. 4, ISSN 1472-4472, pages 627 - 633, XP009110545 | - |
| OPPOSITION | - Aulton Michael E., "Aulton's Pharmaceutics - The Design and Manufacture of Medicines (passage)", Aulton's Pharmaceutics - The Design and Manufacture of Medicines, Third Edition, (20070101), pages 5 - 6, 9, XP093131995 | - |
| OPPOSITION | - Aulton M., "Passage; Chapter 31: Tablets and compaction", Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, Churchill Livingstone Elsevier, (20070101), pages 454 - 455, ISBN 978-0-443-10108-3, XP055926634 | - |
| OPPOSITION | - Beisler J A, et al, "Chemistry of antitumor triazine nucleosides. An improved synthesis of Dihydro-5-AZacytidine", JOURNAL OF CARBOHYDRATES. NUCLEOSIDES NUCLEOTIDES., MARCEL DEKKER, BASEL., CH, CH , (19770101), vol. 4, no. 5, ISSN 0094-0585, pages 281 - 299, XP009089416 | - |
| OPPOSITION | - Calgene Corporation, "Vidaza (azacitidine for injection) for SC or IV use", Highlights of Prescribing Information, (20080801), page 23pp, XP055427458 | - |
| OPPOSITION | - Cheung Yuen-Wah, B. Rao Vishnuvajjala, Nancy L. Morris, Karl P. Flora, "Stability of azacitidine in infusion fluids", American Journal of Hospital Pharmacy, (19840601), vol. 41, pages 1156 - 1159, XP093131360 | - |
| OPPOSITION | - Gibson Mark, "GUIDING PRINCIPLES FOR SIMPLE PARENTERAL SOLUTIONS", Pharmaceutical Preformulation and Formulation, A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, A CRC PRESS BOOK, (20040101), page 332, XP093253796 | - |
| OPPOSITION | - Iarc Working Group, "Azacitidine", WHO: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, (19900101), pages 47 - 63, ISBN 978-92-832-1250-8, XP055429199 | - |
| OPPOSITION | - Kenneth A. Connors, Gordon L. Amidon, Valentino J. Stella, "Passage; 5-Azacytidine", Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, Second Edition, John Wiley & Sons, Inc., (19860101), page 2pp, 239, ISBN 0-471-87955-X, XP055735934 | - |
| OPPOSITION | - Kutschki Ilona, "Akute myeloische Leukämie Erste orale Erhaltungstherapie", DEUTSCHES AERZTEBLATT, DEUTSCHER AERZTE-VERLAG GMBH., COLOGNE, DE, DE , (20210924), vol. 118, no. 38, ISSN 0012-1207, pages A1710 - A1710, XP093205535 | - |
| OPPOSITION | - Lachman Leon, Lieberman Herbert A., Kanic Joseph L., "Delayed-Action and Enteric Coated Tablets", The Theory and Practice of Industrial Pharmacy, 3rd ed., Lea & Febiger, (19860101), pages 331 - 332, ISBN 0-8121-0977-5, XP093132034 | - |
| OPPOSITION | - Leon Shargel, Susanna Wu-Pong, Andrew B.C. Yu, "Modified-Release Drug Products", Applied Biopharmaceutics & Pharmacokinetics Fifth Edition, McGraw-Hill, (20050101), page 2pp, 515, ISBN 0-07-137550-3, XP055735910 | - |
| OPPOSITION | - LIN K.-T., ET AL, "High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine.", Journal of pharmaceutical sciences, Elsevier Inc, Hoboken, Hoboken, (19811101), vol. 70, no. 11, ISSN 0022-3549, pages 1228 - 1232, XP002611849 | - |
| OPPOSITION | - Michael E. Aulton, "Passage; Chapter 31: Tablets and compaction", Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, Churchill Livingstone Elsevier, (20070101), pages 454 - 455, ISBN 978-0-443-10108-3, XP055735913 | - |
| OPPOSITION | - Michael E. Aulton, "PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition /Passage/", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 222 - 223, ISBN 0-443-05517-3, XP055735938 | - |
| OPPOSITION | - Michael E. Aulton, "The transit of pharmaceuticals in the gastrointestinal tract", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 222 - 223, ISBN 0-443-05517-3, XP055735938 | - |
| OPPOSITION | - Mund C; Brueckner B; Lyko F, "Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications", Epigenetics : official journal of the DNA Methylation Society, Landes Bioscience, US, US , (20060301), vol. 1, no. 1, ISSN 1559-2308, pages 7 - 13, XP008109916 | - |
| OPPOSITION | - National Cancer Institute, National Institutes Of Health, "Bioassay of 5-azacytidine for possible carcinogenicity", Carcinogenesis, Technical Report Series No. 42, (19780101), pages 2pp, iii - 4, XP055352926 | - |
| OPPOSITION | - Pithova P et al, "NUCLEIC ACIDS COMPONENTS AND THEIR ANALOGUES. LXVI.* HYDROLYSIS OF 5-AZACYTIDINE AND ITS CONNECTION WITH BIOLOGICAL ACTIVITY", Collection Czechoslov. Chem. Commun., (19650101), vol. 30, pages 2801 - 2811, XP093131982 | - |
| OPPOSITION | - Raymond C Rowe, Paul J Sheskey, Sian C Owen, "HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Fifth Edition /Passage/", HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Fifth Edition, Pharmaceutical Press , (20060101), pages 3pp, 554 - 555, XP055735915 | - |
| OPPOSITION | - Ritschel Wolfgang, "Die Tablette - Handbuch der Entwicklung, Herstellung und Qualitätssicherung. Auszug", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Edito Cantor Verlag , (20020101), pages 30 - 30, ISBN 978-3-87193-228-1, XP093039122 | - |
| OPPOSITION | - Rowland Malcolm, Tozer Thomas, "ANATOMIC AND PHYSIOLOGIC CONSIDERATIONS, ABSORPTION FROM SOLID DOSAGE FORMS", Clinical Pharmacokinetics Concepts and Applications : third edition, (19950101), pages 11-12 - 128-132, XP093253521 | - |
| OPPOSITION | - Vanderhoff Bruce T., Tahboub Rundsarah M., "<mark>Proton pump inhibitors</mark>: <mark>An update</mark>", AMERICAN FAMILY PHYSICIAN, American Academy of Family Physicians, US, US , (20020101), vol. 66, no. 2, ISSN 0002-838X, pages 273 - 280, XP093253769 | - |
| OPPOSITION | - Yvonne Perrie, Thomas Rades, "Chapter 1: Controlling drug delivery ", FASTtrack: Pharmaceutics: Drug Delivery and Targeting; Second Edition , Pharmaceutical Press, (20100101), pages 1 - 24, ISBN 978-0-85369-762-6, XP055924338 | - |
| OPPOSITION | - Carlo Stresemann, Frank Lyko, "Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine", International Journal of Cancer, John Wiley & Sons, Inc., US, US , (20080701), vol. 123, no. 1, doi:10.1002/ijc.23607, ISSN 0020-7136, pages 8 - 13, XP055233070 | |
| OPPOSITION | - Robert E. Notari, Joyce L. Deyoung, "Kinetics and Mechanisms of Degradation of the Antileukemic Agent 5-Azacytidine in Aqueous Solutions", Journal of Pharmaceutical Sciences, Wiley, United States, United States, (19750701), vol. 64, no. 7, doi:10.1002/jps.2600640704, ISSN 0022-3549, pages 1148 - 1157, XP055735925 | |
| OPPOSITION | - Kenneth K. Chan, Donald D. Giannini, J A Staroscik, W Sadee, "5-Azacytidine Hydrolysis Kinetics Measured by High-pressure Liquid Chromatography and 13C-NMR Spectroscopy", Journal of Pharmaceutical Sciences, Wiley, United States, United States, (19790701), vol. 68, no. 7, doi:10.1002/jps.2600680705, ISSN 0022-3549, pages 807 - 812, XP055735923 | |
| OPPOSITION | - Chabner, B.A.et al, "Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase", Biochemical Pharmacology, Elsevier, US, US , (19731101), vol. 22, no. 21, doi:10.1016/0006-2952(73)90137-8, ISSN 0006-2952, pages 2763 - 2765, XP025886768 | |
| OPPOSITION | - Kurkjian, C. ; Kummar, S. ; Murgo, A.J., "DNA Methylation: Its Role in Cancer Development and Therapy", CURRENT PROBLEMS IN CANCER, MOSBY, ST LOUIS, MO, US, US , (20080901), vol. 32, no. 5, doi:10.1016/j.currproblcancer.2008.08.002, ISSN 0147-0272, pages 187 - 235, XP025470418 | |
| OPPOSITION | - Kissinger, L.D. ; Stemm, N.L., "Determination of the antileukemia agents cytarabine and azacitidine and their respective degradation products by high-performance liquid chromatography", Journal of Chromatography A, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19860226), vol. 353, doi:10.1016/S0021-9673(01)87101-6, ISSN 0021-9673, pages 309 - 318, XP026554325 | |
| OPPOSITION | - Hirayama F., Uekama K., "Cyclodextrin-based controlled drug release system", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (19990301), vol. 36, no. 1, doi:10.1016/S0169-409X(98)00058-1, ISSN 0169-409X, pages 125 - 141, XP002616323 | |
| OPPOSITION | - Garcia-Manero G; Stoltz M L; Ward M R; Kantarjian H; Sharma S, "A pilot pharmacokinetic study of oral azacitidine", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20080612), vol. 22, no. 9, doi:10.1038/leu.2008.145, ISSN 0887-6924, pages 1680 - 1684, XP037784418 | |
| OPPOSITION | - Wei Andrew H., Döhner Hartmut, Pocock Christopher, Montesinos Pau, Afanasyev Boris, Dombret Hervé, Ravandi Farhad, Sayar Hamid, Jang Jun-Ho, Porkka Kimmo, Selleslag Dominik, Sandhu Irwindeep, Turgut Mehmet, Giai Valentina, Ofran Yishai, Kizil Çakar Merih, Botelho De Sousa Aida, Rybka Justyna, Frairia Chiara, Borin Lorenza, Beltrami Germana, Čermák Jaroslav, Ossenkoppele Gert J., La Torre Ignazia, Skikne Barry, Kumar Keshava, Dong Qian, Beach C.L., Roboz Gail J., "Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission", The New England journal of medicine, Massachusetts Medical Society, US, US , (20201224), vol. 383, no. 26, doi:10.1056/NEJMoa2004444, ISSN 0028-4793, pages 2526 - 2537, XP055928137 | |
| OPPOSITION | - Becker Richard C., Spencer Frederick A., "Aspirin", Fibrinolytic and Antithrombotic Therapy: Theory, Practice, and Management , Oxford University Press, (20060427), doi:10.1093/OSO/9780195155648.003.0012, ISBN 978-0-19-756195-9, XP093132019 | |
| OPPOSITION | - Čihák A., Šorm F., "Biochemical effects and metabolic transformations of 5-azacytidine in Escherichia coli", Collection of Czechoslovak Chemical Communications, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic [etc.], (19650101), vol. 30, no. 6, doi:10.1135/cccc19652091, ISSN 0010-0765, pages 2091 - 2102, XP093131355 | |
| OPPOSITION | - Thomson Abr et al, "Influence of Food on the Bioavailability of an Enteric-Coated Tablet Formulation of Omeprazole 20 mg Under Repeated Dose Conditions", CANADIAN JOURNAL OF GASTROENTEROLOGY., MEDICARE PUBL., OAKVILLE, CA, CA , (19970101), vol. 11, no. 8, doi:10.1155/1997/830856, ISSN 0835-7900, pages 663 - 667, XP093132020 | |
| OPPOSITION | - Amy Ziemba, Eugene Hayes, Burgess B. Freeman, Tao Ye, Giuseppe Pizzorno, "Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine", Chemotherapy Research and Practice, (20110101), vol. 2011, doi:10.1155/2011/965826, ISSN 2090-2107, pages 1 - 9, XP055734492 | |
| OPPOSITION | - Khan Cyrus, Pathe Neeta, Fazal Salman, Lister John, Rossetti James M., "Azacitidine in the management of patients with myelodysplastic syndromes", THERAPEUTIC ADVANCES IN HEMATOLOGY, Sage Publications Ltd., GB, GB , (20121201), vol. 3, no. 6, doi:10.1177/2040620712464882, ISSN 2040-6207, pages 355 - 373, XP093205428 | |
| OPPOSITION | - Stoltz Maxine L; Etter Jeffirey B; Obradovic Tanja; Jia Richard, "Development of an oral dosage form of azacitidine: Overcoming challenges in chemistry, formulation, and bioavailability.", Blood, American Society of Hematology, US, US , (20061116), vol. 108, no. 11, doi:10.1182/blood.V108.11.4850.4850, ISSN 0006-4971, page 298B, XP009121611 | |
| OPPOSITION | - Garcia-Manero Guillermo; Gore Steven D.; Kambhampati Suman; Scott Bart L; Tefferi Ayalew; Cogle Christopher R; Edenfield William; Hetzer Joel; Kumar Keshava; Skikne Barry S., "Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes", Blood, American Society of Hematology, US, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.424.424, ISSN 0006-4971, page 424, XP086659772 | |
| OPPOSITION | - Ward M. R., Stoltz M.L., Etter J.B., Patton L.M., Garcia Manero G., Sharma S., "7084 - An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", Journal of Clinical Oncology, (20070620), vol. 25, no. 18_suppl., doi:10.1200/jco.2007.25.18_suppl.7084, page 7084, XP093132028 | |
| OPPOSITION | - Guillermo Garcia-Manero, Steven D. Gore, Christopher Cogle, Renee Ward, Tao Shi, Kyle J. Macbeth, Eric Laille, Heidi Giordano, Sarah Sakoian, Elias Jabbour, Hagop Kantarjian, Barry Skikne, "Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia", Journal of Clinical Oncology, Grune & Stratton, (20110620), vol. 29, no. 18, doi:10.1200/JCO.2010.34.4226, ISSN 0732-183X, pages 2521 - 2527, XP055637078 | |
| OPPOSITION | - Vaishali A Kilor, Nidhi P. Sapkal, Jasmine G. Awari, And Bharti D. Shewale, "Development and Characterization of Enteric-Coated Immediate-Release PeHcts of Acedofenac by Extrusion/Spheronization Tedmi<Jm..' lJsing K.-Canageenan as a PeUetizing Agent", AAPS PharmSciTech, (20100301), vol. 11, no. 1, doi:10.1208/s12249-010-9389-9, pages 336 - 343, XP055637096 | |
| OPPOSITION | - KAMINSKAS E ET AL, "FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza(TM)) for injectable suspension", THE ONCOLOGIST, (20050301), vol. 10, no. 3 , doi:10.1634/theoncologist.10-3-176, ISSN 1083-7159, pages 176 - 182, XP002803407 | |
| OPPOSITION | - Christopher R Cogle, Bart L. Scott, Thomas Boyd And Guillermo Garcia-Manero, "Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia", The Oncologist, (20150101), vol. 20, doi:10.1634/theoncologist.2015-0165, pages 1 - 9, XP055637090 | |
| OPPOSITION | - Giuseppe Leone, Francesco D’alò1 , Giuseppe Zardo#,2 , Maria Teresa Voso1 And Clara Nervi#,3, "Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias", Current medicinal chemistry, Bentham, NL, NL , (20080101), vol. 15, no. 13, doi:10.2174/092986708784534947, ISSN 0929-8673, pages 1274 - 1287, XP055924347 | |
| OPPOSITION | - Paul M. Howell, Liu Zixing, Khong Hung T., "Demethylating Agents in the Treatment of Cancer", Pharmaceuticals, M D P I AG, CH, CH , (20100701), vol. 3, no. 7, doi:10.3390/ph3072022, ISSN 1424-8247, pages 2022 - 2044, XP055051867 | |
| SEARCH | - STOLTZ, "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability", ASH ANNUAL MEETING, (20060101), vol. 108, XP009121611 [Y] 1-5 * the whole document * | |
| SEARCH | - WARD, "An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", JOURNAL OF CLINICAL ONCOLOGY, (20070701), vol. 25, no. 18S, XP009121612 [Y] 1-5 * the whole document * | |
